Cvrx, Inc. Stock Price, News & Analysis

CVRx, a medical device company focused on neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:00 am Eastern Time. The presentation will be available via a live audio webcast on the company’s investor relations page. CVRx’s primary product, the Barostim™ System, is the first FDA-approved medical technology using neuromodulation to alleviate heart failure symptoms. The device has received FDA Breakthrough Device designation and CE Mark approvals for heart failure and resistant hypertension.

CVRx has launched the new Barostim NEO2 Implantable Pulse Generator (IPG) in the U.S., enhancing patient and physician experiences during heart failure therapy. The device is 10% smaller and offers a 20% increase in battery life, reducing replacement frequency. It features a simplified design with a single lead port, improving implantation ease. The Barostim NEO2 retains the clinically proven Barostim Therapy while providing a more convenient option for patients and healthcare providers.

CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will participate in two investor conferences on November 17, 2022, in New York, NY. The conferences include the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 13th Annual Craig-Hallum Alpha Select Conference. CVRx's flagship product, Barostim, is the first FDA-approved technology aimed at treating heart failure through neuromodulation, and it has also received CE Mark approval in Europe.

CVRx reported third quarter 2022 revenue of $6.2 million, an 82% increase year-over-year. U.S. Heart Failure revenue nearly doubled to $4.9 million, driven by an expansion in sales territories and increased awareness of Barostim. Active implanting centers in the U.S. grew to 91, a 28% increase from the previous quarter. Gross profit rose to $4.8 million with a gross margin of 78%. However, the net loss widened to $9.8 million. The company expects 2022 revenue between $21.8 million and $22.3 million, with a new $50 million debt facility in place.

CVRx, a medical device company, will release its third quarter 2022 financial results on November 1, 2022, after market close. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time on the same day and will be available via webcast. CVRx focuses on innovative neuromodulation solutions, including Barostim™, the first FDA-approved device for heart failure treatment, which uses electrical pulses to enhance baroreflex and autonomic nervous system balance. Barostim has also received CE Mark approval in Europe.

CVRx, a medical device company, announced its management team's presentation at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 8:30 am ET. The event can be accessed via a live audio webcast on the company's investor relations page. CVRx specializes in neuromodulation solutions for cardiovascular diseases, particularly the Barostim device, which is FDA-approved for heart failure treatment. Barostim uses electrical pulses to enhance the baroreflex, aiming to alleviate heart failure symptoms. Learn more at cvrx.com.

CVRx reported Q2 2022 revenue of $5.0 million, up 61% year-over-year, with U.S. Heart Failure revenue reaching $3.8 million, a 90% increase. Active implanting centers grew by 27% to 71. Gross profit rose to $3.8 million with a gross margin of 76%, driven by lower costs and higher selling prices. However, SG&A expenses surged 122% to $12.5 million, leading to a net loss of $11.1 million. CVRx anticipates full-year revenue between $20.5 million and $23.0 million, slightly raising earlier guidance. Regulatory approval for a new programmer was also received.

CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, plans to release its second quarter 2022 financial results on July 28, 2022, after market close. A conference call to discuss these results will take place at 5:30 p.m. Eastern Time the same day. The event will be available via webcast and telephone registration is recommended. CVRx's flagship product, Barostim, is an FDA-approved device aimed at alleviating heart failure symptoms by enhancing the autonomic nervous system's balance.

CVRx, Inc launches its new Barostim Programmer, enhancing programming for the Barostim therapy for heart failure. Approved by the FDA, this second-generation device incorporates a modern design, upgraded cellular capabilities, and a user-friendly interface, facilitating easier programming of implantable pulse generators. CEO Nadim Yared emphasized the improvements in hardware and software, aimed at better customer support. The rollout across the U.S. market is scheduled throughout 2022.